In September, the FDA approved topical ruxolitinib cream (Opzelura, Incyte) as the first JAK inhibitor to treat AD. Del Rosso noted its list of indications could expand in the near future. Recently released Phase 3 clinical trial program data shows positive outcomes for this JAK inhibitor in treating vitiligo and AA.

News Alert

New Treatment Options

RESEARCH

Resources for Dermatologist treating patients with Vitiligo in Florida

Are you looking for a dermatologist to treat your vitiligo? Are you located in Central Florida area? 

 

Click on the link below to schedule an appointment with Dr. Seth Forman our medical advisor's practice is located in the Tampa area.

MEDIA COVERAGE

AS SEEN ON

download (15).png

I'm a paragraph. Click here to add your own text and edit me. It's easy.